PhosLo

This page contains recent news articles, when available, and an overview of PhosLo but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Nabi Biopharmaceuticals and NIAID to Advance PentaStaph Vaccine ...  -  Sep 9, 2008
...obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, GlobeNewsWire (press release),

Fresenius kaufen  -  Sep 11, 2008
...-dienstleistungen sowie der Erweiterung des Portfolios für Arzneimittel im Dialysesegment (neben Phosphatbinder Phoslo, Eisenpräparate, Vitamin D ua). AktienCheck,

Fresenius SE St.: kaufen (Bankhaus Lampe KG)  -  Aug 29, 2008
...-dienstleistungen sowie der Erweiterung des Portfolios für Arzneimittel im Dialysesegment (neben Phosphatbinder Phoslo, Eisenpräparate, Vitamin D ua). FinanzNachrichten.de,

Fresenius Medical Q2 Earnings Rise, Beat Estimates; Confirms FY08 ...  -  Jul 30, 2008
The operating income also rose significantly due to continued strong performance of renal products including PhosLo. Four analysts polled by First RTT News,

Nabi Biopharmaceuticals Announces Arbitration Settlement With ...  -  Aug 5, 2008
...obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, FOXBusiness

BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology ...  -  Jul 26, 2008
Both Fresenius Medical Care's PhosLo and calcium carbonate continue to be impacted by concerns with calcium, although calcium binders are expected to remain FOXBusiness

Nabi Biopharmaceuticals Announces Positive Interim Results of ...  -  Jul 23, 2008
...receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, and manufacture our pipeline products, MarketWatch

Nabi Biopharmaceuticals Announces Second Quarter 2008 Financial ...  -  Aug 7, 2008
...obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, Trading Markets (press release),

UPDATE: FMC bestätigt nach gutem Quartal Jahresprognose  -  Jul 30, 2008
Der Anstieg sei auf einen starken Absatz im gesamten Produktsortiment einschließlich des Phosphatbinders Phoslo zurückzuführen, erläuterte das Unternehmen. FOCUS Online,

Fresenius Medical Care kaufen - Bankhaus Lampe  -  Jul 30, 2008
...-dienstleistungen sowie der Erweiterung des Portfolios für Arzneimittel im Dialysesegment (neben Phosphatbinder Phoslo, Eisenpräparate, Vitamin D ua). Stock World,

Fresenius Medical Care Confirms Outlook for 2008  -  Jul 30, 2008
This performance was led by strong sales among the whole product portfolio including the phosphate binding drug PhosLo ® .(reed more in the attached file) lifepr.de,

Nabi Biopharmaceuticals lands another $2.5M for drug  -  Jun 4, 2008
Under a deal potentially worth up to $150 million to sell its PhosLo brand to Fresenius USA Manufacturing Inc. a year and a half ago, the Rockville biotech Milwaukee Business Journal,

Other News To Note  -  Jun 3, 2008
...of Walnut Creek, Calif., for the completion of another milestone governing the company's 2006 sale of PhosLo (calcium acetate) and the product's related TMCnet

Nabi Biopharmaceuticals Announces Receipt of $2.5 Million ...  -  Jun 3, 2008
..."I am very pleased that we have achieved yet another milestone toward realizing the significant remaining value of our PhosLo revenue stream," said Dr. RedOrbit,

Genzyme’s Renvela well known, still looking to carve its niche  -  May 23, 2008
...representatives seemed to have ramped up their product promotion, especially compared to their competitors—Fresenius’ PhosLo and Shire’s Fosrenol. Renal Business Today,

Nabi Biopharmaceuticals Announces First Quarter 2008 Financial Results  -  May 8, 2008
...obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, CNNMoney.com (press release)

ESA use decreases in pre-dialysis patients, study says  -  May 7, 2008
In CKD care, the report said calcium-based binders are preferred with Fresenius’ PhosLo being the market leader with a 43 percent share. Renal Business Today,

BioTrends Releases Two Publications - TreatmentTrends(TM ...  -  May 6, 2008
In the CKD setting, calcium-based binders are preferred and Fresenius Medical Care's PhosLo is the market share leader with 43% share. Biloxi Sun Herald,

Nabi Settles Suit Against Roxane Labs  -  Apr 3, 2008
In 2005, Nabi filed a lawsuit against Roxane Labs for infringement of its patent for PhosLo GelCaps, after Roxane applied with the Food and Drug CNNMoney.com

Roundup: Nabi, CACI, Freddie  -  Apr 3, 2008
...*Nabi Biopharmacetuicals of Rockville said it settled a patent case against Roxane Laboratories related to its former product PhosLo Gelcaps. Washington Post,

Kidney patients get vascular help  -  Apr 22, 2008
As a result of this and similar studies, the Food and Drug Administration has now approved the use of PhosLo, Renagel and Fosrenol for the treatment of high Belleville News Democrat,

Phosphate-reducing drugs could curb heart disease in kidney patients  -  Apr 18, 2008
Recently, the FDA extended the label of phosphate binding drugs, which include calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate CBC.ca,

Nabi reaches settlement in patent dispute  -  Apr 3, 2008
The case regarding PhosLo GelCaps was dismissed from the US District Court for the Southern District of Ohio after Nabi reached a settlement with Columbus, Bizjournals.com,

Readily available treatment could help prevent heart disease in ...  -  Apr 17, 2008
As a result, calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) will be labeled to indicate they are approved for treatment of News from Washington University in St. Louis,

Nabi Biopharmaceuticals Announces Settlement of Litigation  -  Apr 3, 2008
On November 12, 2006, Nabi completed the sale of PhosLo and related intellectual property to Fresenius USA Manufacturing, Inc. While Fresenius assumed PharmaLive.com (press release),

Fresenius Medical Care Reports Excellent Fourth Quarter and Full ...  -  Feb 21, 2008
In North America, the operating margin increased from 17.1% (excluding the effects of one-time items) by 70 basis points to 17.8% due to the new PhosLo FOXBusiness

Fresenius Medical Net Rises on Dialysis Treatments (Update5)  -  Feb 20, 2008
US dialysis services revenue was unchanged, while the sale of machines and the PhosLo drug drove product revenue up 17 percent in that market. Bloomberg

Nabi Biopharmaceuticals Announces Fourth Quarter and Full- Year ...  -  Feb 29, 2008
...obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, PharmaLive.com (press release),

Nabi Biopharmaceuticals Initiates New Strategic Alternatives Process  -  Jan 22, 2008
Nabi has re-emerged with a strong balance sheet, a significant potential PhosLo milestone and royalty stream, and a focused vaccine pipeline. CNNMoney.com

Nabi, of Rockville, explores alternatives  -  Jan 23, 2008
PhosLo, used to reduce excess blood phosphorus, has potential for up to $75 million in royalty payments during the next decade, the company said. Baltimore Sun,

Nabi Biopharmaceuticals Names Dr. Raafat EF Fahim as President and ...  -  Jan 22, 2008
...obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, CNNMoney.com

BioTrends Releases Fourth Annual Nephrology TreatmentTrends ...  -  Jan 28, 2008
Binder preference also remains similar to last year with calcium-based binders (such as Fresenius Medical Care's PhosLo) dominating 2:1 in the pre-dialysis Earthtimes,

Fresnius Medical Care says new phoslo drug data confirms positive ...  -  Nov 7, 2007
7, 2007 (Thomson Financial delivered by Newstex) -- Fresenius Medical Care (NYSE:FMS) AG said additional data on its phoslo drug from the Calcium Renagel CNNMoney.com

Fresenius Medical Care Announces Continued Positive Data from CARE ...  -  Nov 7, 2007
The study showed that there are no significant differences in aortic or mitral valve calcification between hemodialysis patients treated with phoslo and lifepr.de,

ROUNDUP Fresenius Medical gains as Q3 opg beats forecasts on high ...  -  Oct 31, 2007
The North America business, the company's largest, benefited from a hike in average revenue per treatment and strong demand for its Phoslo pill. CNNMoney.com

Fresenius Medical Q3 opg up 14 pct, beats forecasts on high-margin ...  -  Oct 31, 2007
Sales of Phoslo, which abates excess amounts of phosphate in dialysis patients' blood, jumped 79 pct, meeting the company's expectations, Fresenius Medical Forbes,

Study Probes Best Choice of Drug to Reduce Phosphate in Patients ...  -  Nov 6, 2007
In this study, 200 patients on maintenance dialysis were randomized to either phoslo or Renagel; participants in both groups also were treated with Journal of American Medical Association (subscription),

Fresenius Medical Care Reports Strong Third Quarter and Nine ...  -  Oct 31, 2007
Dialysis Product revenue increased by 18% to $167 million led by strong sales of our 2008K hemodialysis machines and the phosphate binding drug phoslo. Genetic Engineering News (press release),

German shares close lower after disappointing Bank of America Q3 ...  -  Oct 18, 2007
...from gains yesterday after media reports said that the FDA could approve wider use of its phoslo drug for kidney disease in pre-dialysis treatments. Forbes,

Nabi gets sale nod from proxy firms  -  Nov 4, 2007
Nabi also will retain the right to receive up to an additional $75 million in milestone and royalty payments related to the divestiture of phoslo in Boca Raton News,

Genzyme, Shire, Fresenius seek to broaden drug use  -  Oct 12, 2007
Shire, a British drug company, makes Fosrenol, while Fresenius of Germany makes PhosLo. Genzyme makes the kidney disease drug Renagel. Reuters.uk,

Phosphate Binder for Dialysis May Lower Mortality Rates in Older ...  -  Aug 31, 2007
The calcium binders used were either calcium acetate (PhosLo), or calcium carbonate (Tums) for those patients who could not tolerate calcium acetate. MedPage Today,

Genzyme Announces Publication of DCOR Study in Kidney International  -  Aug 30, 2007
Approximately 30 percent of patients in the calcium group opted to use calcium carbonate rather than PhosLo. Patients were treated according to the usual All American Patriots (press release),

Fresenius Medical Q2 EBIT up 5 pct at 391 mln usd as sales rises ...  -  Aug 1, 2007
Forbes,In North America, the operating margin excluding one-offs rose by 140 basis points to 17.2 pct partly due to the new Phoslo business and higher product

Nabi Biopharmaceuticals Announces Creation of Biologics Business ...  -  Jun 18, 2007
PR Newswire (press release),...as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate).

Fresenius Medical Care Reports Outstanding Start for 2007 and ...  -  May 2, 2007
Genetic Engineering News (press release),Dialysis Product revenue increased by 14% to $153 million led by strong sales of our 2008K hemodialysis machines and the phosphate binding drug PhosLo.

Nabi to sell drug to Irish pharmaceutical firm  -  Apr 20, 2007
Charlotte Business Journal,The company has already sold off one other marketed product, PhosLo, as well as another product in development, to Fresenius Medical Care for up to $150

Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year ...  -  Apr 3, 2007
Drug Newswire (press release),Revenues for both years excluded sales of PhosLo(R) (calcium acetate) which are included in discontinued operations. Revenues for the fourth quarter of 2006

Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim  -  Apr 20, 2007
PharmaLive.com (press release),...as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate).

American Kidney Fund launches Part D grant program  -  Apr 3, 2007
Renal Business Today,The program covers bone disease medications, including Fosrenol, Hecterol, Phoslo, Renagel, Sensipar and Zemplar. Burton added that the AKF hopes to add

American Kidney Fund Launches Medicare Part D Grant Program for ...  -  Apr 3, 2007
PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®.

Recap of South Florida's best, worst in '06  -  Dec 31, 2006
Miami Herald,Earlier this month, Nabi signed a contract to sell its top producing drug, PhosLo, for $150 million to give it much-needed cash for other projects.

Nabi survives year of tumult, but future still cloudy  -  Dec 2, 2006
Palm Beach Post,And its PhosLo deal with Fresenius AG might bring the German drugmaker back for more. Baxter Healthcare Corp. in Deerfield, Ill., might be an acquirer of

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.